Key market opportunities in Q1 2026 include significant regulatory catalysts like approvals for GSK's depemokimab, Regenxbio's gene therapy, and Omeros' narsoplimab. Ongoing trials by Xenon, Cerevel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback